Surge in Options Trading: EchoStar, RxSight, and Blueprint Medicines Take Center Stage
In a significant trading day for the Russell 3000 index, EchoStar Corp (Symbol: SATS) attracted attention with a remarkable options trading volume. So far today, a total of 7,947 contracts have changed hands, equating to around 794,700 underlying shares. This figure represents about 59.7% of SATS’s average daily trading volume of 1.3 million shares over the past month. A notable highlight includes the $28 strike call option expiring on November 15, 2024, which recorded 2,508 contracts trading today—approximately 250,800 underlying shares. The chart below illustrates SATS’s trailing twelve-month trading history, with the $28 strike marked in orange:
Similarly, RxSight Inc (Symbol: RXST) shows impressive options activity with 1,884 contracts traded, representing nearly 188,400 underlying shares. This volume accounts for approximately 59.3% of RXST’s monthly average daily trading volume of 317,490 shares. The $40 strike put option set to expire on November 15, 2024, saw increased interest as well, with 1,778 contracts trading—illustrating about 177,800 underlying shares. Below is RXST’s trailing twelve-month trading history, with the $40 strike emphasized in orange:
Meanwhile, Blueprint Medicines Corp (Symbol: BPMC) reported trading volume of 3,789 contracts, equivalent to about 378,900 underlying shares, or 58.4% of BPMC’s monthly average daily volume of 648,855 shares. The $100 strike put option expiring on December 19, 2025, drew particular interest, with 3,084 contracts traded—representing approximately 308,400 underlying shares. The chart below shows BPMC’s trailing twelve-month trading data, highlighting the $100 strike in orange:
For information on various expiration options available for SATS, RXST, or BPMC, please visit StockOptionsChannel.com.
Today’s Most Active Call & Put Options of the S&P 500 »
Also see:
- ITC Price Target
- IAC Stock Predictions
- RCAT Stock Predictions
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
